Quarterly report pursuant to Section 13 or 15(d)

Marketable Securities

v3.19.1
Marketable Securities
3 Months Ended
Mar. 31, 2019
Investments, Debt and Equity Securities [Abstract]  
Marketable Securities
3. Marketable Securities
Marketable securities at March 31, 2019 consisted of the following:
 
Marketable Securities
 
Amortized Cost
 
 
Unrealized

Gains
 
 
Unrealized

Losses
 
 
Fair Value
 
Current:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corporate debt
 
$
13,265,522
 
 
$
732
 
 
$
(78
)
 
$
13,266,176
 
U.S. Treasury securities
 
 
3,001,071
 
 
 
382
 
 
 
 
 
 
3,001,453
 
 
 
$
16,266,593
 
 
$
1,114
 
 
$
(78
)
 
$
16,267,629
 
Marketable securities at December 31, 2018 consisted of the following:
 
Marketable Securities
 
Amortized Cost
 
 
Unrealized

Gains
 
 
Unrealized

Losses
 
 
Fair Value
 
Current:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corporate debt
 
$
19,179,530
 
 
$
314
 
 
$
(31,160
)
 
$
19,148,684
 
U.S. Treasury securities
 
 
2,982,706
 
 
 
546
 
 
 
 
 
 
2,983,252
 
 
 
$
22,162,236
 
 
$
860
 
 
$
(31,160
)
 
$
22,131,936
 
U.S. Treasury securities include government debt instruments issued by the U.S. Department of the Treasury. Corporate debt includes obligations issued by investment-grade corporations, and may include issues that have been guaranteed by governments and government agencies. At March 31, 2019 
and December 31, 2018, the Company held only investments that have maturities of less than one year.
At March 31, 2019 and December 31, 2018, the Company held 11 and 21 debt securities, respectively, that individually and in total were in an immaterial unrealized loss position for less than one year. The aggregate fair value of debt securities in an unrealized loss position at March 31, 2019 and December 31, 2018 was $10,570,964 and $18,551,296, respectively. The Company evaluated its securities for other-than-temporary impairment and considered the decline in market value for the securities to be primarily attributable to current economic and market conditions. It is not more likely than not that the Company will be required to sell the securities prior to the recovery of the amortized cost basis. Based on this analysis, these marketable securities were not considered to be other-than-temporarily impaired as of March 31, 2019 and December 31, 2018.